Factors affecting abdominal pressure in peritoneal dialysis for polycystic kidney disease
Studies abdominal pressure measures and estimates in adults with polycystic kidney disease on dialysis.
Plain-language title generated from the registry record
Registry title: The Factors Affecting IPP in Peritoneal Dialysis Patients with Polycystic Kidney Disease
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with polycystic kidney disease who are on regular peritoneal dialysis. It studies the pressure inside the belly during dialysis.
- Age
- 18 to 80 years
- Sex
- Women and men can join.
- Disease stage
- Confirmed polycystic kidney disease, on regular peritoneal dialysis with a dialysis catheter placed.
- Earlier treatment
- A history of peritoneal dialysis catheter placement and regular peritoneal dialysis.
Main reasons for not taking part
- Peritonitis or heart or brain blood vessel events in the past month
- Abdominal surgery or injury in the past month
- Kidney cyst rupture, infection or bleeding in the past month
- History of tumors of the abdominal or pelvic organs
- History of belly pressure problems such as hernias, leaks or chest-abdominal fistulas
This trial only enrols participants on dialysis. The registry sentence this rests on: A confirmed diagnosis of polycystic kidney disease, with a history of peritoneal dialysis catheter placement and regular peritoneal dialysis;
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06841224, who can take part
Where in China
- Peking University First HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT06841224
- Record updated
- 24 February 2025
- Original description
Background: Polycystic kidney disease (PKD) is the most common hereditary kidney disease. Peritoneal dialysis (PD) in such patients is restricted because the significantly enlarged kidneys and liver may lead to the increase of intraperitoneal pressure (IPP). Increased IPP points to higher risk of abdominal wall complications and limited infusion volume that cause insufficient dialysis adequacy. Therefore, monitoring IPP is especially important in patients with polycystic kidney disease. However, the standard measurement of IPP is limited due to its cumbersome procedures, the application value of equation for estimating IPP among general peritoneal dialysis patients is not clear in the PKD population and the variables influence the IPP is yet to be explored..Read full original descriptionShow less
The Factors Affecting IPP in Peritoneal Dialysis Patients with Polycystic Kidney Disease
Background: Polycystic kidney disease (PKD) is the most common hereditary kidney disease. Peritoneal dialysis (PD) in such patients is restricted because the significantly enlarged kidneys and liver may lead to the increase of intraperitoneal pressure (IPP). Increased IPP points to higher risk of abdominal wall complications and limited infusion volume that cause insufficient dialysis adequacy. Therefore, monitoring IPP is especially important in patients with polycystic kidney disease. However, the standard measurement of IPP is limited due to its cumbersome procedures, the application value of equation for estimating IPP among general peritoneal dialysis patients is not clear in the PKD population and the variables influence the IPP is yet to be explored..
Objective: The main purpose of our study was to validate the existing IPP equations in the PKD patients. Further, more relevant variables were included to optimize the IPP equation. Monitoring IPP can guide the formulation of peritoneal dialysis prescription for ADPKD patients, reduce the occurrence of abdominal wall complications, and the clinical utility and efficiency of PD was expanded.
Methods: A multi-center cross-sectional study. The IPPs were measured using the Durand method, with whole-body and abdominal anthropometry indices, the volume of abdominal cavity, the total kidney volume and liver volume were collected. New equation for estimate IPP in PKD patients were generated by stepwise linear regression modeling. The eIPP were calculated using two developed equations previously. Then The bias, accuracy and precision of eIPP derived from new equation were compared with actual IPP by Durand method respectively.
Inclusion: Aged 18-80 years; A confirmed diagnosis of polycystic kidney disease, with a history of peritoneal dialysis catheter placement and regular peritoneal dialysis; Able to tolerate the infusion of more than 1500 mL of dialysis fluid.
Exclusion: History of abdominal surgery or trauma within the past month; History of kidney cyst rupture, infection, or bleeding within the past month; History of abdominal or pelvic organ tumors; History of abdominal pressure-related complications, such as hernias, leaks, or chest-abdominal fistulas; Acute complications such as peritonitis or cardiovascular and cerebrovascular events within the past month; Unable to attend follow-up visits during the study period; Refusal to participate in the study. -.